MYOK stock forecast
Our latest prediction for MyoKardia, Inc.'s stock price was made on the Feb. 3, 2020 when the stock price was at 69.29$.
In the short term (2weeks), MYOK's stock price should underperform the market by -2.37%. During that period the price should oscillate between -8.74% and +7.31%.
In the medium term (3months), MYOK's stock price should underperform the market by -4.43%. During that period the price should oscillate between -32.16% and +17.46%.Get email alerts
About MyoKardia, Inc.
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.
At the moment the company generates 12M USD in revenues.
On its last earning announcement, the company reported a loss of -5.29$ per share.
The book value per share is 9.64$
Three months stock forecastFeb. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|